Autem Therapeutics
Biotechnology ResearchView the employees at
Autem Therapeutics-
Amy Howard Independent Consultant
-
Walpole, New Hampshire, United States
-
Rising Star
Davide Lazzari Biomedical Engineer | Politecnico di Torino | Bionanotechnologies-
Rising Star
Cornelia Bauer Durand Mura Vice President of Commercial Operations at Autem Therapeutics-
Top 5%
Frederico Perego Costa Founder & Chief Scientific Officer at Autem Therapeutics-
São Paulo, São Paulo, Brazil
-
Top 10%
Alan Machado Coelho Engenheiro de software na Autem Therapeutics-
São Paulo, São Paulo, Brazil
-
Rising Star
Overview
Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers. The company has received FDA breakthrough designation for its AutEMsys™ therapy for the treatment of advanced HCC patients. The AutEMsys™ therapy delivers personalized, amplitude-modulated electromagnetic (EM) frequencies (and based on initial clinical feasibility studies shows promise in shrinking cancerous tumors, enhancing quality of life and extending survival in early and advanced stage cancer patient populations. Autem Therapeutics anticipates submitting an FDA Investigational Device Exemption (IDE) to initiate FDA pivotal clinical trials in late 2022 or early 2023.
-